- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 38/20 - Interleukines
Détention brevets de la classe A61K 38/20
Brevets de cette classe: 5165
Historique des publications depuis 10 ans
|
257
|
331
|
422
|
424
|
512
|
455
|
497
|
430
|
365
|
257
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Iovance Biotherapeutics, Inc. | 411 |
102 |
| The Regents of the University of California | 20868 |
67 |
| Massachusetts Institute of Technology | 10290 |
58 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3339 |
53 |
| Immunitybio, Inc. | 513 |
52 |
| Altor BioScience, LLC | 80 |
51 |
| The Board of Trustees of the Leland Stanford Junior University | 6707 |
50 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3325 |
45 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3016 |
41 |
| Novartis AG | 10174 |
38 |
| Memorial Sloan-Kettering Cancer Center | 2058 |
36 |
| Nektar Therapeutics | 401 |
35 |
| Regeneron Pharmaceuticals, Inc. | 4800 |
35 |
| Bristol-myers Squibb Company | 4757 |
34 |
| The Trustees of the University of Pennsylvania | 4435 |
34 |
| Genentech, Inc. | 4123 |
31 |
| Genexine, Inc. | 109 |
31 |
| Dana-Farber Cancer Institute, Inc. | 2671 |
30 |
| Philogen S.p.A. | 128 |
30 |
| Xencor, Inc. | 410 |
29 |
| Autres propriétaires | 4283 |